FDA Grants Approval for Hydrocortisone ANDA218298 by Rising
The FDA has granted an Abbreviated New Drug Application (ANDA) approval for Hydrocortisone submitted by Rising.
Published: July 23, 2026
Updated: July 23, 2026
Author: Humanexa Intelligence
Therapeutic area: Dermatology / Corticosteroid
Asset: FDA
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
FDA
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval of Rising's hydrocortisone ANDA218298 introduces a new competitor into the dermatology corticosteroid market. This development could disrupt pricing and market share dynamics, necessitating strategic adjustments from existing players.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market response and sales performance of Rising's hydrocortisone product post-launch.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.